High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: the HUNT study

2.

Arshad

N

,

Bjøri

E

,

Hindberg

K

,

Isaksen

T

,

Hansen

JB

,

Braekkan

SK

.

Recurrence and mortality after first venous thromboembolism in a large population-based cohort

.

J Thromb Haemost

.

2017

;

15

(

2

):

295

-

303

.

3.

Schulman

S

,

Lindmarker

P

,

Holmstrom

M

, et al.

Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months

.

J Thromb Haemost

.

2006

;

4

(

4

):

734

-

742

.

4.

Klok

FA

,

van der Hulle

T

,

den Exter

PL

,

Lankeit

M

,

Huisman

MV

,

Konstantinides

S

.

The post-PE syndrome: a new concept for chronic complications of pulmonary embolism

.

Blood Rev

.

2014

;

28

(

6

):

221

-

226

.

5.

Jørgensen

H

,

Horváth-Puhó

E

,

Laugesen

K

,

Brækkan

S

,

Hansen

JB

,

Sørensen

HT

.

Risk of a permanent work-related disability pension after incident venous thromboembolism in Denmark: a population-based cohort study

.

PLoS Med

.

2021

;

18

(

8

):

e1003770

.

6.

Jørgensen

H

,

Horváth-Puhó

E

,

Laugesen

K

,

Brækkan

SK

,

Hansen

JB

,

Sørensen

HT

.

Venous thromboembolism and risk of depression: a population-based cohort study

.

J Thromb Haemost

.

2023

;

21

(

4

):

953

-

962

.

7.

Arshad

N

,

Isaksen

T

,

Hansen

JB

,

Braekkan

SK

.

Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population

.

Eur J Epidemiol

.

2017

;

32

(

4

):

299

-

305

.

8.

Munster

AM

,

Rasmussen

TB

,

Falstie-Jensen

AM

, et al.

A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015

.

Thromb Res

.

2019

;

176

:

46

-

53

.

9.

Engbers

MJ

,

van Hylckama Vlieg

A

,

Rosendaal

FR

.

Venous thrombosis in the elderly: incidence, risk factors and risk groups

.

J Thromb Haemost

.

2010

;

8

(

10

):

2105

-

2112

.

10.

World Health Organization

.

Fact sheet: obesity and overweight

. Accessed 1 August 2023. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.

11.

Bray

F

,

Ferlay

J

,

Soerjomataram

I

,

Siegel

RL

,

Torre

LA

,

Jemal

A

.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

.

CA Cancer J Clin

.

2018

;

68

(

6

):

394

-

424

.

12.

Bartel

DP

.

MicroRNAs: target recognition and regulatory functions

.

Cell

.

2009

;

136

(

2

):

215

-

233

.

13.

Paul

P

,

Chakraborty

A

,

Sarkar

D

, et al.

Interplay between miRNAs and human diseases

.

J Cell Physiol

.

2018

;

233

(

3

):

2007

-

2018

.

14.

Saliminejad

K

,

Khorram Khorshid

HR

,

Soleymani Fard

S

,

Ghaffari

SH

.

An overview of microRNAs: biology, functions, therapeutics, and analysis methods

.

J Cell Physiol

.

2019

;

234

(

5

):

5451

-

5465

.

15.

Mitchell

PS

,

Parkin

RK

,

Kroh

EM

, et al.

Circulating microRNAs as stable blood-based markers for cancer detection

.

Proc Natl Acad Sci U S A

.

2008

;

105

(

30

):

10513

-

10518

.

16.

Kirschner

MB

,

van Zandwijk

N

,

Reid

G

.

Cell-free microRNAs: potential biomarkers in need of standardized reporting

.

Front Genet

.

2013

;

4

:

56

.

17.

Anijs

RJS

,

Nguyen

YN

,

Cannegieter

SC

,

Versteeg

HH

,

Buijs

JT

.

MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism

.

J Thromb Haemost

.

2023

;

21

(

1

):

7

-

17

.

18.

Rupaimoole

R

,

Slack

FJ

.

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

.

Nat Rev Drug Discov

.

2017

;

16

(

3

):

203

-

222

.

19.

van Rooij

E

,

Kauppinen

S

.

Development of microRNA therapeutics is coming of age

.

EMBO Mol Med

.

2014

;

6

(

7

):

851

-

864

.

20.

Morelli

VM

,

Brækkan

SK

,

Hansen

JB

.

Role of microRNAs in venous thromboembolism

.

Int J Mol Sci

.

2020

;

21

(

7

):

2602

.

21.

Xiao

J

,

Jing

ZC

,

Ellinor

PT

, et al.

MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

.

J Transl Med

.

2011

;

9

:

159

.

22.

Starikova

I

,

Jamaly

S

,

Sorrentino

A

, et al.

Differential expression of plasma miRNAs in patients with unprovoked venous thromboembolism and healthy control individuals

.

Thromb Res

.

2015

;

136

(

3

):

566

-

572

.

23.

Kessler

T

,

Erdmann

J

,

Vilne

B

, et al.

Serum microRNA-1233 is a specific biomarker for diagnosing acute pulmonary embolism

.

J Transl Med

.

2016

;

14

(

1

):

120

.

24.

Wang

X

,

Sundquist

K

,

Elf

JL

, et al.

Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis

.

Thromb Haemost

.

2016

;

116

(

2

):

328

-

336

.

25.

Sahu

A

,

Jha

PK

,

Prabhakar

A

, et al.

MicroRNA-145 impedes thrombus formation via targeting tissue factor in venous thrombosis

.

EBioMedicine

.

2017

;

26

:

175

-

186

.

26.

Sun

S

,

Chai

S

,

Zhang

F

,

Lu

L

.

Overexpressed microRNA-103a-3p inhibits acute lower-extremity deep venous thrombosis via inhibition of CXCL12

.

IUBMB Life

.

2019

;

72

(

3

):

492

-

504

.

27.

Wang

X

,

Sundquist

K

,

Svensson

PJ

, et al.

Association of recurrent venous thromboembolism and circulating microRNAs

.

Clin Epigenetics

.

2019

;

11

(

1

):

28

.

28.

Thibord

F

,

Munsch

G

,

Perret

C

, et al.

Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis

.

Eur Heart J Suppl

.

2020

;

22

(

Suppl C

):

C34

-

C45

.

29.

Zhang

Y

,

Zhang

Z

,

Wei

R

, et al.

IL (interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p

.

Arterioscler Thromb Vasc Biol

.

2020

;

40

(

2

):

323

-

334

.

30.

Gabler

J

,

Basílio

J

,

Steinbrecher

O

,

Kollars

M

,

Kyrle

PA

,

Eichinger

S

.

MicroRNA signatures in plasma of patients with venous thrombosis: a preliminary report

.

Am J Med Sci

.

2021

;

361

(

4

):

509

-

516

.

31.

Nafady

A

,

Rashad

A

,

Nafady-Hego

H

, et al.

Clinical significance of miRNA-145 and -126 in chronic obstructive pulmonary disease with pulmonary embolism

.

Clin Lab

.

2022

;

68

(

7

).

32.

Ten Cate

V

,

Rapp

S

,

Schulz

A

, et al.

Circulating microRNAs predict recurrence and death following venous thromboembolism

.

J Thromb Haemost

.

2023

;

21

(

10

):

2797

-

2810

.

33.

Sennblad

B

,

Basu

S

,

Mazur

J

, et al.

Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels

.

Hum Mol Genet

.

2017

;

26

(

3

):

637

-

649

.

34.

Villadsen

SB

,

Bramsen

JB

,

Ostenfeld

MS

, et al.

The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer

.

Br J Cancer

.

2012

;

106

(

2

):

366

-

374

.

35.

Manly

DA

,

Boles

J

,

Mackman

N

.

Role of tissue factor in venous thrombosis

.

Annu Rev Physiol

.

2011

;

73

:

515

-

525

.

36.

Meijers

JC

,

Tekelenburg

WL

,

Bouma

BN

,

Bertina

RM

,

Rosendaal

FR

.

High levels of coagulation factor XI as a risk factor for venous thrombosis

.

N Engl J Med

.

2000

;

342

(

10

):

696

-

701

.

37.

Salomon

O

,

Steinberg

DM

,

Zucker

M

,

Varon

D

,

Zivelin

A

,

Seligsohn

U

.

Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

.

Thromb Haemost

.

2011

;

105

(

2

):

269

-

273

.

38.

Frischmuth

T

,

Hindberg

K

,

Aukrust

P

, et al.

Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism

.

J Thromb Haemost

.

2022

;

20

(

7

):

1618

-

1626

.

39.

Ye

D

,

Shen

Z

,

Zhou

S

.

Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment

.

Cancer Manag Res

.

2019

;

11

:

969

-

979

.

40.

Sawant

D

,

Lilly

B

.

MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways

.

Vasc Biol

.

2020

;

2

(

1

):

R115

-

r128

.

41.

Krokstad

S

,

Langhammer

A

,

Hveem

K

, et al.

Cohort profile: the HUNT Study, Norway

.

Int J Epidemiol

.

2013

;

42

(

4

):

968

-

977

.

42.

Hagen

K

,

Stovner

LJ

,

Nilsen

KB

,

Kristoffersen

ES

,

Winsvold

BS

.

The impact of C-reactive protein levels on headache frequency in the HUNT study 2006-2008

.

BMC Neurol

.

2019

;

19

(

1

):

229

.

43.

Wang

X

,

Sundquist

J

,

Zoller

B

, et al.

Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2

.

PLoS One

.

2014

;

9

(

1

):

e86792

.

44.

Bye

A

,

Røsjø

H

,

Aspenes

ST

,

Condorelli

G

,

Omland

T

,

Wisløff

U

.

Circulating microRNAs and aerobic fitness--the HUNT-Study

.

PLoS One

.

2013

;

8

(

2

):

e57496

.

45.

Ameling

S

,

Kacprowski

T

,

Chilukoti

RK

, et al.

Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study

.

BMC Med Genomics

.

2015

;

8

:

61

.

46.

Folsom

AR

,

Lutsey

PL

,

Astor

BC

,

Cushman

M

.

C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort

.

Thromb Haemost

.

2009

;

102

(

4

):

615

-

619

.

47.

Horvei

LD

,

Grimnes

G

,

Hindberg

K

, et al.

C-reactive protein, obesity, and the risk of arterial and venous thrombosis

.

J Thromb Haemost

.

2016

;

14

(

8

):

1561

-

1571

.

48.

He

M

,

Wu

N

,

Leong

MC

, et al.

miR-145 improves metabolic inflammatory disease through multiple pathways

.

J Mol Cell Biol

.

2020

;

12

(

2

):

152

-

162

.

49.

Shahrokhi

SZ

,

Saeidi

L

,

Sadatamini

M

,

Jafarzadeh

M

,

Rahimipour

A

,

Kazerouni

F

.

Can miR-145-5p be used as a marker in diabetic patients?

.

Arch Physiol Biochem

.

2022

;

128

(

5

):

1175

-

1180

.

50.

Clarke

R

,

Shipley

M

,

Lewington

S

, et al.

Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies

.

Am J Epidemiol

.

1999

;

150

(

4

):

341

-

353

.

51.

Kadkhoda

S

,

Ghafouri-Fard

S

.

Function of miRNA-145-5p in the pathogenesis of human disorders

.

Pathol Res Pract

.

2022

;

231

:

153780

.

52.

Timp

JF

,

Braekkan

SK

,

Versteeg

HH

,

Cannegieter

SC

.

Epidemiology of cancer-associated venous thrombosis

.

Blood

.

2013

;

122

(

10

):

1712

-

1723

.

53.

Nopp

S

,

Kraemmer

D

,

Ay

C

.

Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence

.

Front Cardiovasc Med

.

2022

;

9

:

903029

.